Healthcare Global Enterprises Limited has informed the Exchange that the Competition Commission of India vide its letter dated 1 May 2025 has approved the sale of upto 54% of voting share capital of the Company from Aceso Company Pte. Ltd to Hector Asia Holdings II Pte. Ltd., KIA EBT II Scheme 1.
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.6 pts more than Nifty Microcap 250 and 3.6 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Healthcare Global Enterprises (HCG) has informed the exchanges that the Competition Commission of India (CCI) has approved the sale of up to 54% of the company's voting share capital from Aceso Company Pte. Ltd. (Seller) to Hector Asia Holdings II Pte. Ltd. and KIA EBT II Scheme 1 (Purchasers). This follows the share purchase agreement signed on 23 February 2025 between the parties. CCI approved the deal at its meeting held on 1 May 2025 under Section 31(1) of the Competition Act, 2002. The detailed order from CCI is still awaited. This is a key regulatory clearance required for the change in controlling shareholding of the listed oncology hospital chain.
This clearance removes a major regulatory hurdle for the change of ownership at HCG, paving the way for Hector Asia Holdings and KIA EBT II Scheme 1 to become new promoters. Shareholders should watch for the next steps, including potential mandatory open offer obligations under SEBI Takeover Regulations given the 54% stake size.